Skip to main content
Erschienen in: Osteoporosis International 2/2015

01.02.2015 | REVIEW

Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials

verfasst von: Y.-T. Li, H.-F. Cai, Z.-L. Zhang

Erschienen in: Osteoporosis International | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Summary

We performed a systematic review and meta-analysis of randomized clinical trials. Early administration of bisphosphonates (BPs) after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.

Introduction

Bisphosphonates (BPs) are widely used in the prophylaxis and treatment of osteoporosis. However, early administration of BPs after surgical repair of a fracture may limit the reserve capacity of bone to heal. The aim of this review and meta-analysis was to analyze the benefits and adverse effects of early administration of BPs and give recommendations regarding when BPs should be utilized.

Methods

We identified randomized controlled trials comparing the early administration of BPs to placebo, delayed BP treatment, or no therapy in adult patients after surgery. The search was performed in PubMed, the Cochrane Library, and Embase.

Results

Ten studies with 2888 patients were included. Four trials used alendronate, three trials used zoledronic, two trials used risedronate, and one trial used etidronate. Early administration of BPs was considered less than 3 months after surgery. Patients treated with BP therapy had no significant differences in radiological fracture healing times compared with patients in the control group (mean difference [MD] 0.47, 95 % confidence interval [CI] −2.75 to 3.69). There were also no significant differences in the rate of delay or nonunion of fracture healing (odds ratio [OR] 0.98, 95 % CI 0.64 to 1.50). However, the bone mineral density (BMD) of total hips did significantly improve after 12 months of treatment with BPs. And most bone turnover markers of patients in the study group were significantly decreased.

Conclusions

Early administration of BPs after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, according to the changes in BMD and bone turnover markers, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.
Literatur
5.
Zurück zum Zitat von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS (2005) Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26(34):6941–6949. doi:10.1016/j.biomaterials.2005.04.059 CrossRef von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS (2005) Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26(34):6941–6949. doi:10.​1016/​j.​biomaterials.​2005.​04.​059 CrossRef
6.
Zurück zum Zitat Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, Luo XH (2009) A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 119(12):3666–3677. doi:10.1172/JCI39832 PubMedCentralPubMedCrossRef Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, Luo XH (2009) A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 119(12):3666–3677. doi:10.​1172/​JCI39832 PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301. doi:10.1210/jc.2004-0952 PubMedCrossRef Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301. doi:10.​1210/​jc.​2004-0952 PubMedCrossRef
10.
Zurück zum Zitat Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 17(12):2237–2246. doi:10.1359/jbmr.2002.17.12.2237 CrossRef Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 17(12):2237–2246. doi:10.​1359/​jbmr.​2002.​17.​12.​2237 CrossRef
12.
Zurück zum Zitat Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 14(6):969–979. doi:10.1359/jbmr.1999.14.6.969 CrossRef Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 14(6):969–979. doi:10.​1359/​jbmr.​1999.​14.​6.​969 CrossRef
13.
Zurück zum Zitat Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 16(3):429–436. doi:10.1359/jbmr.2001.16.3.429 CrossRef Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 16(3):429–436. doi:10.​1359/​jbmr.​2001.​16.​3.​429 CrossRef
14.
Zurück zum Zitat Bauss F, Schenk RK, Hort S, Muller-Beckmann B, Sponer G (2004) New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 50(1):25–34. doi:10.1016/j.vascn.2003.11.003 PubMedCrossRef Bauss F, Schenk RK, Hort S, Muller-Beckmann B, Sponer G (2004) New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 50(1):25–34. doi:10.​1016/​j.​vascn.​2003.​11.​003 PubMedCrossRef
15.
Zurück zum Zitat Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res: Off J Am Soc Bone Miner Res 19(11):1779–1786. doi:10.1359/JBMR.040814 CrossRef Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res: Off J Am Soc Bone Miner Res 19(11):1779–1786. doi:10.​1359/​JBMR.​040814 CrossRef
16.
Zurück zum Zitat Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, Schmidmaier G (2008) Local application of zoledronic acid incorporated in a poly(D, L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop 79(5):717–725. doi:10.1080/17453670810016768 PubMedCrossRef Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, Schmidmaier G (2008) Local application of zoledronic acid incorporated in a poly(D, L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop 79(5):717–725. doi:10.​1080/​1745367081001676​8 PubMedCrossRef
17.
Zurück zum Zitat Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML (2009) Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg 34(4):595–602. doi:10.1016/j.jhsa.2008.12.011 CrossRef Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML (2009) Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg 34(4):595–602. doi:10.​1016/​j.​jhsa.​2008.​12.​011 CrossRef
18.
Zurück zum Zitat Amanat N, Brown R, Bilston LE, Little DG (2005) A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res: Off Publ Orthop Res Soc 23(5):1029–1034. doi:10.1016/j.orthres.2005.03.004 CrossRef Amanat N, Brown R, Bilston LE, Little DG (2005) A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res: Off Publ Orthop Res Soc 23(5):1029–1034. doi:10.​1016/​j.​orthres.​2005.​03.​004 CrossRef
19.
Zurück zum Zitat Goodship AE, Walker PC, McNally D, Chambers T, Green JR (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5(Suppl 7):S53–S55PubMed Goodship AE, Walker PC, McNally D, Chambers T, Green JR (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5(Suppl 7):S53–S55PubMed
20.
Zurück zum Zitat Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res: Off J Am Soc Bone Miner Res 20(11):2044–2052. doi:10.1359/JBMR.050712 CrossRef Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res: Off J Am Soc Bone Miner Res 20(11):2044–2052. doi:10.​1359/​JBMR.​050712 CrossRef
21.
Zurück zum Zitat Bransford R, Goergens E, Briody J, Amanat N, Cree A, Little D (2007) Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Section Cervical Spine Res Soc 16(4):557–562. doi:10.1007/s00586-006-0212-y CrossRef Bransford R, Goergens E, Briody J, Amanat N, Cree A, Little D (2007) Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Section Cervical Spine Res Soc 16(4):557–562. doi:10.​1007/​s00586-006-0212-y CrossRef
23.
Zurück zum Zitat Benlebna F, El AF, Boumediene ZB, El KM, Medghar S, Djaroud Z (2011) Delay of consolidation and bisphosphonates: two cases. Ann Phys Rehabil Med 54:e182–e183CrossRef Benlebna F, El AF, Boumediene ZB, El KM, Medghar S, Djaroud Z (2011) Delay of consolidation and bisphosphonates: two cases. Ann Phys Rehabil Med 54:e182–e183CrossRef
24.
Zurück zum Zitat Czerwinski E, Osieleniec J, Loranc A (2011) Delayed union after atypical subtrochanteric fracture under alendronate treatment: case report. Osteoporos Int 22:S220CrossRef Czerwinski E, Osieleniec J, Loranc A (2011) Delayed union after atypical subtrochanteric fracture under alendronate treatment: case report. Osteoporos Int 22:S220CrossRef
25.
Zurück zum Zitat Li C, Wang HR, Li XL, Zhou XG, Dong J (2012) The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochir (Wien) 154(4):731–738. doi:10.1007/s00701-012-1283-7 CrossRef Li C, Wang HR, Li XL, Zhou XG, Dong J (2012) The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochir (Wien) 154(4):731–738. doi:10.​1007/​s00701-012-1283-7 CrossRef
26.
Zurück zum Zitat Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing, vol 22. Osteoporos Int. doi:10.1007/s00198-010-1473-1 Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing, vol 22. Osteoporos Int. doi:10.​1007/​s00198-010-1473-1
27.
Zurück zum Zitat Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, Trial HRF (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. doi:10.1056/NEJMoa074941 PubMedCrossRef Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, Trial HRF (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. doi:10.​1056/​NEJMoa074941 PubMedCrossRef
28.
Zurück zum Zitat Ng AJ, Yue B, Joseph S, Richardson M (2014) Delayed/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations. ANZ J Surg 84(4):218–224. doi:10.1111/ans.12536 PubMedCrossRef Ng AJ, Yue B, Joseph S, Richardson M (2014) Delayed/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations. ANZ J Surg 84(4):218–224. doi:10.​1111/​ans.​12536 PubMedCrossRef
29.
Zurück zum Zitat Uchiyama S, Itsubo T, Nakamura K, Fujinaga Y, Sato N, Imaeda T, Kadoya M, Kato H (2013) Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J 95-B(11):1544–1550. doi:10.1302/0301-620x.95b11.31652 PubMedCrossRef Uchiyama S, Itsubo T, Nakamura K, Fujinaga Y, Sato N, Imaeda T, Kadoya M, Kato H (2013) Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J 95-B(11):1544–1550. doi:10.​1302/​0301-620x.​95b11.​31652 PubMedCrossRef
30.
31.
Zurück zum Zitat Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH (2012) Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures, vol 94. J Bone Joint Surg Am Vol. doi:10.2106/jbjs.k.01434 Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH (2012) Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures, vol 94. J Bone Joint Surg Am Vol. doi:10.​2106/​jbjs.​k.​01434
33.
Zurück zum Zitat Harding AK, Toksvig-Larsen S, Tagil M, W-Dahl A (2010) A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. Bone 46(3):649–654. doi:10.1016/j.bone.2009.10.040 PubMedCrossRef Harding AK, Toksvig-Larsen S, Tagil M, W-Dahl A (2010) A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. Bone 46(3):649–654. doi:10.​1016/​j.​bone.​2009.​10.​040 PubMedCrossRef
35.
Zurück zum Zitat Altintas F, Ozkut AT, Beyzadeoglu T, Eren A, Guven M (2007) The effect of risedronate treatment on bone turnover markers in patients with hip fracture. Acta Orthop Traumatol Turc 41(2):132–135PubMed Altintas F, Ozkut AT, Beyzadeoglu T, Eren A, Guven M (2007) The effect of risedronate treatment on bone turnover markers in patients with hip fracture. Acta Orthop Traumatol Turc 41(2):132–135PubMed
38.
Zurück zum Zitat Boonen S, Orwoll E, Magaziner J, Colon-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59(11):2084–2090. doi:10.1111/j.1532-5415.2011.03666.x PubMedCrossRef Boonen S, Orwoll E, Magaziner J, Colon-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59(11):2084–2090. doi:10.​1111/​j.​1532-5415.​2011.​03666.​x PubMedCrossRef
39.
Zurück zum Zitat Adachi JD, Lyles K, Boonen S, Colon-Emeric C, Hyldstrup L, Nordsletten L, Pieper C, Recknor C, Su G, Bucci-Rechtweg C, Magaziner J (2011) Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-Recurrent Fracture Trial. Calcif Tissue Int 89(6):427–433. doi:10.1007/s00223-011-9543-8 PubMedCentralPubMedCrossRef Adachi JD, Lyles K, Boonen S, Colon-Emeric C, Hyldstrup L, Nordsletten L, Pieper C, Recknor C, Su G, Bucci-Rechtweg C, Magaziner J (2011) Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-Recurrent Fracture Trial. Calcif Tissue Int 89(6):427–433. doi:10.​1007/​s00223-011-9543-8 PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Colon-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S (2011) Clinical risk factors for recurrent fracture after hip fracture: a prospective study. Calcif Tissue Int 88(5):425–431. doi:10.1007/s00223-011-9474-4 PubMedCrossRef Colon-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S (2011) Clinical risk factors for recurrent fracture after hip fracture: a prospective study. Calcif Tissue Int 88(5):425–431. doi:10.​1007/​s00223-011-9474-4 PubMedCrossRef
41.
Zurück zum Zitat Adachi JD, Lyles KW, Colon-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS (2011) Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int 22(9):2539–2549. doi:10.1007/s00198-010-1514-9 PubMedCrossRef Adachi JD, Lyles KW, Colon-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS (2011) Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int 22(9):2539–2549. doi:10.​1007/​s00198-010-1514-9 PubMedCrossRef
42.
Zurück zum Zitat Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22(8):2329–2336. doi:10.1007/s00198-010-1473-1 PubMedCrossRef Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22(8):2329–2336. doi:10.​1007/​s00198-010-1473-1 PubMedCrossRef
43.
Zurück zum Zitat Boonen S, Black DM, Colon-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292–299. doi:10.1111/j.1532-5415.2009.02673.x PubMedCentralPubMedCrossRef Boonen S, Black DM, Colon-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292–299. doi:10.​1111/​j.​1532-5415.​2009.​02673.​x PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25(1):91–97. doi:10.1359/jbmr.090704 PubMedCrossRef Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25(1):91–97. doi:10.​1359/​jbmr.​090704 PubMedCrossRef
45.
Zurück zum Zitat Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313. doi:10.1359/jbmr.090209 PubMedCrossRef Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313. doi:10.​1359/​jbmr.​090209 PubMedCrossRef
46.
Zurück zum Zitat Colon-Emeric CS, Caminis J, Suh TT, Pieper CF, Janning C, Magaziner J, Adachi J, Rosario-Jansen T, Mesenbrink P, Horowitz ZD, Lyles KW (2004) The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin 20(6):903–910. doi:10.1185/030079904125003683 PubMedCrossRef Colon-Emeric CS, Caminis J, Suh TT, Pieper CF, Janning C, Magaziner J, Adachi J, Rosario-Jansen T, Mesenbrink P, Horowitz ZD, Lyles KW (2004) The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin 20(6):903–910. doi:10.​1185/​0300799041250036​83 PubMedCrossRef
48.
Zurück zum Zitat Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282. doi:10.1210/jc.2012-1027 PubMedCrossRef Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282. doi:10.​1210/​jc.​2012-1027 PubMedCrossRef
49.
Zurück zum Zitat Goldhahn J, Feron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W, Mitlak B, Tsouderos Y, Boonen S (2012) Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 90(5):343–353. doi:10.1007/s00223-012-9587-4 PubMedCrossRef Goldhahn J, Feron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W, Mitlak B, Tsouderos Y, Boonen S (2012) Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 90(5):343–353. doi:10.​1007/​s00223-012-9587-4 PubMedCrossRef
51.
52.
Zurück zum Zitat Coates P (2013) Bone turnover markers. Aust Fam Physician 42(5):285–287PubMed Coates P (2013) Bone turnover markers. Aust Fam Physician 42(5):285–287PubMed
Metadaten
Titel
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials
verfasst von
Y.-T. Li
H.-F. Cai
Z.-L. Zhang
Publikationsdatum
01.02.2015
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 2/2015
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2903-2

Weitere Artikel der Ausgabe 2/2015

Osteoporosis International 2/2015 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.